Corporate Update – Zhejiang Hisun Pharmaceutical (600267.SS)
Market Performance Snapshot
- Current trading session: flat 0 % as of 05:22 PM Central Europe on Tuesday, 20 Oct 2026.
- Trade‑price: CNY 13.27 on major exchanges.
- Shares outstanding: 1.1 billion.
- Market capitalization: CNY 12.7 billion.
- 24‑hour turnover: CNY 118.4 million, representing 0.93 % of the total shares.
- Monthly change: up 1.6 % since the end of September.
- 200‑day SMA: CNY 11.41.
- 52‑week high/low: CNY 15.00 (14 Aug 2026) / CNY 9.35 (22 Jun 2026).
Q1 2026 Earnings – A Strategic Upswing
Zhejiang Hisun Pharmaceutical released its first‑quarter results for 2026, reporting a notable increase in net profit compared with the corresponding period last year. The company attributes the lift to:
| Driver | Impact |
|---|---|
| Robust sales of innovative therapeutics | Expanded production scale, cost absorption |
| Growth in the pet‑health portfolio | Diversified revenue streams |
| Divestiture of a subsidiary | One‑off gain contributing to earnings lift |
Operating revenue is expected to trail last year slightly following the divestiture, yet the net profit margin has moved decisively higher. This trajectory underscores the firm’s disciplined approach to cost optimisation and portfolio rationalisation.
Market Context – Peer Activity
| Stock | Symbol | Change (24 h) | Current Price | Market Cap | P/E |
|---|---|---|---|---|---|
| Sf Diamond | 300179.SZ | 0 % | CNY 31.28 | CNY 15.2 bn | 126.84 |
| Green Development Electric | 000537.SZ | 0 % | CNY 7.20 | CNY 15.1 bn | 31.72 |
| Liaoning Cheng Da | 600739.SS | 0 % | CNY 9.94 | CNY 15.2 bn | 9.34 |
| Shanghai Fullhan Microelec | 300613.SZ | 0 % | CNY 67.73 | CNY 15.2 bn | 31.15 |
| Bgi Genomics | 300676.SZ | 0 % | CNY 41.98 | CNY 15.1 bn | – |
The broader Shanghai Composite index edged higher on the day, while the Shenzhen component and ChiNext index dipped marginally. Sectors anchored in AI PCs, humanoid robotics, and brain‑computer interfaces recorded gains, whereas traditional heavy‑industry sectors (coal, non‑ferrous metals, shipping) saw declines. Within healthcare, diagnostics and genomics players captured significant upside, reflecting investor optimism for future profitability and dividend potential.
Forward‑Looking Outlook
With its Q1 earnings signalling a sustained profit margin improvement, Zhejiang Hisun Pharmaceutical is poised to continue scaling its innovative drug pipeline while capitalising on the growing pet‑health market. The divestiture proceeds, coupled with a leaner cost base, provide a buffer for the company to navigate potential macro‑economic headwinds. Investors should monitor the company’s pipeline roll‑out, regulatory approvals, and any subsequent divestiture activity that could further enhance shareholder value.
About Zhejiang Hisun Pharmaceutical
Founded in 2000 and listed on the Shanghai Stock Exchange (ticker 600267.SS) on 5 July 2000, Zhejiang Hisun Pharmaceutical Co., Ltd. operates out of Taizhou, China. The company specialises in the development, manufacture, and distribution of a broad spectrum of pharmaceutical products, including anticancer agents, cardiovascular therapeutics, anti‑parasitics, and anti‑infectives. Additionally, it offers comprehensive pharmaceutical solution services. More detailed information is available on the company’s website: www.hisunpharm.com .
